LNTH — Lantheus Holdings, Inc.

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1521036 ·
Last close
$101.80
Market Cap
$6.66B
52W High
$111.86
52W Low
$51.84
ADV30
1,022,256
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 388,180,000 241,855,000 100,215,000 75,029,000 2,414,662,000 593,298,000 1,102,884,000
Mar 2026 377,333,000 230,922,000 81,326,000 118,417,000 2,346,587,000 498,582,000 1,134,299,000
Dec 2025 406,786,000 240,875,000 77,184,000 54,088,000 2,227,399,000 359,121,000 1,137,602,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$412,802,000
Investing CF
$-307,015,000
Financing CF
$-207,070,000
CapEx
$-24,971,000
Dividends Paid
—
Buybacks
$-200,017,000
EPS Diluted TTM
$4.06
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$872,950,000
Inventory
$57,551,000
Receivables
$354,056,000
ST Investments
—
EBIT TTM
$382,783,000
Pretax Income TTM
$362,976,000
Interest Exp TTM
$19,807,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,562,211,968
EBITDA
$354,720,000
Free Cash Flow
$403,712,384
Enterprise Value
$6,520,709,120
Total Cash
$683,609,984
Total Debt
$624,283,008
Shares Out
65,401,413
Trailing EPS
$4.02
Book Value
$20.74
ROE
21.8%
ROA
7.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,541,609,000 315,559,000 233,559,000 2,227,399,000 1,137,602,000 1,089,797,000 390,141,000
Dec 2024 1,533,910,000 448,564,000 312,442,000 1,980,340,000 892,329,000 1,088,011,000 544,750,000
Dec 2023 1,296,429,000 364,642,000 326,661,000 1,651,149,000 835,257,000 815,892,000 305,260,000
Dec 2022 935,061,000 36,195,000 28,067,000 1,321,258,000 874,111,000 447,147,000 281,781,000

TTM Snapshot

Revenues TTM
$1,556,313,000
NetIncome TTM
$275,305,000
OpCashFlow TTM
—
Assets (Latest)
$2,414,662,000
Forward EPS
$6.48

Peers — same industry

TickerNameMarket CapLastDaily %
ICLR ICON PLC $15.05B $195.02 —
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $15.92B $332.16 —
MEDP Medpace Holdings, Inc. $18.27B $653.09 —
NEOG NEOGEN CORP $2.38B $10.90 —
CLDX Celldex Therapeutics, Inc. $2.20B $28.04 —

News headlines (Yahoo Finance, 1h cache)

Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer’s Disease
2026-11-16 14:00 · Yahoo
PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
2026-11-09 21:05 · Yahoo
Lantheus Holdings: Q3 Earnings Snapshot
2026-11-05 12:22 · Yahoo
Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
2026-11-05 12:15 · Yahoo
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
2026-11-02 13:30 · Yahoo
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
2026-09-30 12:30 · Yahoo
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
2026-09-28 12:00 · Yahoo
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval
2026-09-26 18:10 · Yahoo
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval
2026-09-26 02:08 · Yahoo
3 Reasons LNTH is Risky and 1 Stock to Buy Instead
2026-09-23 13:57 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.